Incidence of serious gastrointestinal events and inflammatory bowel disease among tildrakizumab-treated patients with moderate-to-severe plaque psoriasis: Data from 3 large randomized clinical trials

被引：0
|
作者：
Gooderham, Melinda [1 ]
Elewski, Boni [2 ]
Pariser, David [3 ,4 ]
Sofen, Howard [5 ]
Mendelsohn, Alan [6 ]
Cichanowitz, Nicole [7 ]
Li, Qing [7 ]
la Rosa, Carmen [7 ]
机构：
[1] Prob Med Res & Skin Ctr Dermatol, Peterborough, ON, Canada
[2] Univ Alabama Birmingham, Sch Med, Birmingham, AL USA
[3] Eastern Virginia Med Sch, Williamsburg, VA USA
[4] Virginia Clinical Res Inc, Norfolk, VA USA
[5] Univ Calif Los Angeles, Dept Med Dermatol, Los Angeles, CA 90024 USA
[6] Sun Pharmaceut, Philadelphia, PA USA
[7] Merck & Co Inc, Kenilworth, NJ USA
来源：
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2018年 / 79卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
7092
引用
收藏
页码：AB166 / AB166
页数：1
相关论文
共 50 条
  • [31] Inflammatory bowel disease among patients with psoriasis treated with ixekizumab: A presentation of adjudicated data from an integrated database of 7 randomized controlled and uncontrolled trials
    Reich, Kristian
    Leonardi, Craig
    Langley, Richard G.
    Warren, Richard B.
    Bachelez, Herve
    Romiti, Ricardo
    Ohtsuki, Mamitaro
    Xu, Wen
    Acharya, Nayan
    Solotkin, Kathleen
    Colombel, Jean-Frederic
    Hardin, Dana S.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2017, 76 (03) : 441 - +
  • [32] Rapid onset of action in patients with moderate-to-severe psoriasis treated with brodalumab: A pooled analysis of data from two phase 3 randomized clinical trials (AMAGINE-2 and AMAGINE-3)
    Blauvelt, Andrew
    Papp, Kim A.
    Lebwohl, Mark G.
    Green, Lawrence J.
    Hsu, Sylvia
    Bhatt, Varsha
    Rastogi, Shipra
    Pillai, Radhakrishnan
    Israel, Robert
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2017, 77 (02) : 372 - 374
  • [33] Median time to treatment response in patients with moderate-to-severe plaque psoriasis treated with brodalumab 210 mg or ustekinumab: A pooled analysis of data from two phase 3 randomized clinical trials (AMAGINE-2 and AMAGINE-3)
    Blauvelt, Andrew
    Lebwohl, Mark
    Green, Lawrence
    Hsu, Sylvia
    Bhatt, Varsha
    Rastogi, Shipra
    Israel, Robert
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2017, 76 (06) : AB167 - AB167
  • [34] Long-term safety profile of ixekizumab in patients with moderate-to-severe plaque psoriasis: an integrated analysis from 11 clinical trials
    Langley, R. G.
    Kimball, A. B.
    Nakagawa, H.
    Xu, W.
    Pangallo, B.
    Osuntokun, O. O.
    Agada, N.
    Reich, K.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2019, 33 (02) : 333 - 339
  • [35] Long-term safety of tildrakizumab in patients with moderate-to-severe psoriasis: pooled analysis through 148 weeks from two phase 3 trials
    Reich, K.
    Thaci, D.
    Pau-Charles, I.
    Igarashi, A.
    Ohtsuki, M.
    Lebwohl, M.
    Cantrell, W.
    Rozzo, S.
    Blauvelt, A.
    Iversen, L.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2019, 33 : 47 - 48
  • [36] Prevalence of Inflammatory Bowel Disease Among Patients With Psoriasis and Incidence of Serious Infections in This Subset: Results From the PSOLAR Registry
    Loftus, Edward V.
    Augustin, Matthias
    Bissonnette, Robert
    Krueger, Gerald
    Calabro, Stephen
    Langholff, Wayne
    Popp, Jay
    Goyal, Kavitha
    Sloan, Sheldon
    GASTROENTEROLOGY, 2016, 150 (04) : S805 - S805
  • [37] Evaluation of inflammatory bowel disease in patients with plaque psoriasis studied in phase 3 trials of ixekizumab (UNCOVER Trials): Adjudicated data from the induction period
    Langley, R.
    Romiti, R.
    Leonardi, C.
    Reich, K.
    Warren, R. B.
    Ohtsuki, M.
    Xu, W.
    Solotkin, K.
    Hardin, D.
    Bachelez, H.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2016, 136 (09) : S169 - S169
  • [38] Evaluation of inflammatory bowel disease in patients with plaque psoriasis studied in phase 3 trials of ixekizumab (UNCOVER trials): Adjudicated data from the induction period
    Langley, Richard
    Romiti, Ricardo
    Leonardi, Craig
    Reich, Kristian
    Warren, Richard
    Solotikin, Kathleen
    Xu, Wen
    Vangerow, Harald
    Hardin, Dana
    Bachelez, Herve
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2016, 74 (05) : AB249 - AB249
  • [39] NO INCREASED RISK OF INFLAMMATORY BOWEL DISEASE AMONG SECUKINUMAB-TREATED PATIENTS WITH MODERATE TO SEVERE PSORIASIS, PSORIATIC ARTHRITIS, OR ANKYLOSING SPONDYLITIS: DATA FROM 14 PHASE 2 AND PHASE 3 CLINICAL STUDIES
    Zochling, J.
    Deodhar, A.
    Schreiber, S.
    Gandhi, K.
    Fox, T.
    Gaillez, C.
    Karyekar, C.
    INTERNAL MEDICINE JOURNAL, 2017, 47 : 38 - 39
  • [40] No Increased Risk of Inflammatory Bowel Disease Among Secukinumab-Treated Patients with Moderate to Severe Psoriasis, Psoriatic Arthritis, or Ankylosing Spondylitis: Data from 14 Phase 2 and Phase 3 Clinical Studies
    Deodhar, Atul A.
    Schreiber, Stefan
    Gandhi, Kunal
    Fox, Todd
    Gaillez, Corine
    Karyekar, Chetan
    ARTHRITIS & RHEUMATOLOGY, 2016, 68
12345